Generally speaking, sentiment on this particular segment of healthcare is mixed, though it’s interesting to note that each member of this trio has gained at least 4.5% year-to-date.
At a 4.4% yield, AbbVie pays the highest dividend in S&P 500’s entire healthcare sector, and Abbott offers a much more modest yield of 1.6%. Ariad, meanwhile, is not attractive for income-seeking investors, though Loeb has held the stock since the second quarter of last year. Wall Street’s average price target on Ariad represents an upside of more than 40%, though “monkeys” may be best off by considering all three of these biotech stocks in tandem.
Click here to learn more about Insider Monkey’s Hedge Fund Newsletter
Insider Monkey’s small-cap strategy returned 25.4% between September 2012 and January 2013 versus 7.4% for the S&P 500 index. Try it now by clicking the link above.
Disclosure: none